Health
Molnupiravir (MK-4482/EIDD-2801) Antiviral — Precision Vaccinations – PrecisionVaccinations
Molnupiravir (MK-4482/EIDD-2801) antiviral is indicated to mitigate SARS-CoV-2 infection and block transmission, hence preventing COVID-19 disease.
Molnupiravir (MK-4482/EIDD-2801) Antiviral Description
Molnupiravir (MK-4482/EIDD-2801) is an oral antiviral drug that was originally developed for the treatment of influenza. MK-4482/EIDD-2801 consists of the nucleoside analogue N4-hydroxycytidine (NHC). Molnupiravir has been evaluated against coronaviruses (CoVs) including SARS-1, MERS-CoV, and SARS-CoV-2.
The drug was originally developed at Emory University by the university’s drug innovation company, Drug Innovation Ventures at Emory (DRIVE)….
-
Noosa News21 hours agoTerrifying break-in at childcare centre on Sunshine Coast ends with death of man
-
Noosa News19 hours agoADF to introduce billion-dollar drone dome over Brisbane 2032
-
Noosa News23 hours agoWhy the Story Bridge won’t have a traffic lane repurposed for bikes and walkers
-
General18 hours agoVulnerable youth non-for-profit Allambi Care agrees to end ‘unacceptable’ housing scheme